Table 3.

Comparison of noninvasive biomarkers pre- and post-treatment in the subjects with either noninvasive biomarker-detected advanced hepatic fibrosis (nAHF) using APRI > 0.44 or no evidence of noninvasive biomarker-detected advanced hepatic fibrosis (no nAHF) using APRI ≤ 0.44 in Model 1.

	APRI	Fib4	TE	Hepascore	Ferritin (µg/L)
nAHF
Pre-treatment	0.64 ± 0.05	1.4 ± 0.2	5.9 ± 0.9	0.35 ± 0.06	1118 ± 191
Post-treatment	0.44 ± 0.05*	1.3 ± 0.2	4.5 ± 0.5	0.30 ± 0.08	317 ± 37**
No nAHF
Pre-treatment	0.28 ± 0.01	0.84 ± 0.03	4.9 ± 0.1	0.21 ± 0.01	624 ± 37
Post-treatment	0.30 ± 0.03	0.98 ± 0.13	5.0 ± 0.2	0.20 ± 0.02	338 ± 21***

Results are shown as mean ± SE.

APRI: aspartate aminotransferase to platelet ratio index; Fib4: fibrosis-4; nAHF: noninvasive biomarker advanced hepatic fibrosis; No nAHF: no noninvasive biomarker advanced hepatic fibrosis; TE: transient elastography.

*P < 0.05, **P < 0.01, ***P < 0.0001 compared with pre-treatment (paired t test).